VITEKTA
LOE ApproachingNDAORALTABLET
Approved
Sep 2014
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
2/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VITEKTA is an oral small-molecule antiviral approved by the FDA in September 2014 for the treatment of HIV infection. The drug is part of Gilead Sciences' antiviral portfolio and is administered as a tablet. Specific mechanism of action and indication details are not available in current data.
LOE Approaching9mo to LOE
With loss of exclusivity approaching in April 2027 (0.8 years remaining), the brand team faces imminent generic competition and likely budget reductions, signaling a shift toward defensive strategies and possible team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on VITEKTA at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.